Trial Profile
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary) ; Celecoxib; Cyclophosphamide; Topotecan
- Indications Neuroblastoma
- Focus Adverse reactions
- 07 Feb 2024 Planned End Date changed from 1 Dec 2023 to 30 Dec 2024.
- 18 Jan 2024 According to a Panbela Therapeutics media release, results from this study suggest that CPP-1X is a safe, oral treatment option that may improve response rates in heavily pretreated relapsed refractory neuroblastoma patients and are the basis for the ongoing ANBL-1821 Phase 2 trial.
- 18 Jan 2024 According to a Panbela Therapeutics media release, results from this study published in the British Journal of Cancer investigated the tolerability and activity of depleting polyamines by high dose CPP-1X and celecoxib in combination with standard of care chemotherapy in heavily pretreated neuroblastoma patients.